Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD9829 |
Synonyms | |
Therapy Description |
AZD9829 is an antibody-drug conjugate (ADC) comprising an IL3RA (CD123)-targeted antibody linked to the TOP1 inhibitor AZ14170132, which potentially induces DNA damage and apoptosis in IL3RA (CD123)-expressing cancer cells and inhibits tumor growth (Blood (2023) 142 (Supplement 1): 5957). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD9829 | AZD 9829|AZD-9829 | AZD9829 is an antibody-drug conjugate (ADC) comprising an IL3RA (CD123)-targeted antibody linked to the TOP1 inhibitor AZ14170132, which potentially induces DNA damage and apoptosis in IL3RA (CD123)-expressing cancer cells and inhibits tumor growth (Blood (2023) 142 (Supplement 1): 5957). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06179511 | Phase Ib/II | AZD9829 | Study of AZD9829 in CD123+ Hematological Malignancies | Recruiting | USA | ITA | GBR | ESP | DEU | AUS | 4 |